S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
ETR:BIO

Biotest Aktiengesellschaft - BIO Stock Forecast, Price & News

€43.20
-0.40 (-0.92%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
€43.00
€43.20
50-Day Range
€41.60
€43.60
52-Week Range
€41.00
€44.60
Volume
500 shs
Average Volume
1,927 shs
Market Capitalization
$854.74 million
P/E Ratio
N/A
Dividend Yield
0.19%
Price Target
N/A
BIO stock logo

About Biotest Aktiengesellschaft (ETR:BIO) Stock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BIO Stock News Headlines

Biotest Aktiengesellschaft (BIO3.DE)
ALCON AG
DGAP-Adhoc: Biotest AG: Biotest exceeds Revenue guidance 2021
Biotest AG: Reduction of guidance
DGAP-Adhoc: Biotest AG: Reduction of guidance
Grifols, S.A. (GRFS)
BIOTEST AG ST O.N. (BIO.MU)
BIOTEST AG ST O.N. (BIO.DU)
BIOTEST AG STAMMAKTIEN O.N. (BIO.SG)
Biotest Aktiengesellschaft (0N70.L)
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,967
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$505 million
Cash Flow
€1.34 per share
Book Value
€9.61 per share

Miscellaneous

Free Float
N/A
Market Cap
$854.74 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Dr. Michael Ramroth (Age 60)
    Chairman of the Management Board, CEO & CFO
    Comp: $2.1M
  • Dr. Georg Floß
    COO & Member of the Board of Management
  • Dr. Jorg Schuttrumpf (Age 48)
    Chief Scientific Officer & Member of the Management Board
  • Mr. Peter Janssen (Age 55)
    COO & Member of Management Board
  • Dr. Monika Buttkereit
    Head of Investor Relations
  • Dr. Christina Erb
    Head of Corp. HR
  • Dr. Katrin Bernöster
    Head of the Project Management Organisation
  • Mr. Peter Seith
    Head of Quality Operations
  • Dirk Schuck (Age 44)
    Member of Supervisory Board













BIO Stock - Frequently Asked Questions

How have BIO shares performed in 2022?

Biotest Aktiengesellschaft's stock was trading at €42.70 on January 1st, 2022. Since then, BIO stock has increased by 1.2% and is now trading at €43.20.
View the best growth stocks for 2022 here
.

Is Biotest Aktiengesellschaft a good dividend stock?

Biotest Aktiengesellschaft (ETR:BIO) pays an annual dividend of €0.04 per share and currently has a dividend yield of 0.19%.

What other stocks do shareholders of Biotest Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest Aktiengesellschaft investors own include Grifols (GRFS), CSL (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA).

What is Biotest Aktiengesellschaft's stock symbol?

Biotest Aktiengesellschaft trades on the ETR under the ticker symbol "BIO."

What is Biotest Aktiengesellschaft's stock price today?

One share of BIO stock can currently be purchased for approximately €43.20.

How much money does Biotest Aktiengesellschaft make?

Biotest Aktiengesellschaft (ETR:BIO) has a market capitalization of $854.74 million and generates $505 million in revenue each year.

How many employees does Biotest Aktiengesellschaft have?

The company employs 1,967 workers across the globe.

How can I contact Biotest Aktiengesellschaft?

Biotest Aktiengesellschaft's mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The official website for the company is www.biotest.com. The company can be reached via phone at +49-6103-8010.

This page (ETR:BIO) was last updated on 12/4/2022 by MarketBeat.com Staff